A CRISPR kidney that is part pig, part person is just another step toward editing our children’s genes. Call it sci-fi ...

Crispr Therapeutics AG ( (CRSP) ) has fallen by -7.70%. Read on to learn why.

The obesity rate has more than doubled in the last 30 years, affecting more than one billion people worldwide.

Salk Institute scientists are looking for a new treatment strategy in microproteins, an understudied class of molecules found ...

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Mars, maker of M&M's and Skittles, is turning to CRISPR gene editing to develop more resilient cacao plants, with the aim of ...

Researchers developed a method to dissect immune-regulatory programs via integrative time-series analysis and high-content CRISPR screening.

CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 ...

CRISPR Therapeutics, trading under, operates within the biotechnology sector, a key area of interest within the broader ...

The multiagent AI system, dubbed “CRISPR-GPT,” is designed to interact and reason with human users as they execute ...

By using a protein called Cas9 to find and remove a damaged portion of a genetic sequence and then replace it using a ...

CRISPR Therapeutics (CRSP) stock falls as company's Q2 results miss consensus amid focus on its Cagevy gene therapy developed with Vertex Pharma (VRTX). Read more here.